ESHAP方案治疗复发或难治性侵袭性非霍奇金淋巴瘤  

Clinical study of ESHAP regimen for relapsed or refractory aggressive non-Hodgkin lymphoma

作　　者：罗盛[1] 胡旭东[1] 沈志坚[1] 张君丽[1] 孙岚[1] 陈怡[1] 

机构地区：[1]温州医学院附属第一医院血液内科,325000

出　　处：《肿瘤研究与临床》2007年第11期763-765,共3页Cancer Research and Clinic

摘　　要：目的观察 ESHAP 方案作为解救化疗方案治疗复发或难治性侵袭性非霍奇金淋巴瘤(NHL)的疗效和安全性。方法选取38例复发或难治性侵袭性 NHL 患者,使用 ESHAP 方案(依托泊苷、甲泼尼龙、顺铂、阿糖胞苷)作为解救方案进行化疗。结果 38例患者各接受了2～6个周期 ESHAP方案化疗,总的客观有效率为55.3%,完全缓解率26.3%;主要不良反应为骨髓抑制伴感染,均可耐受。结论 ESHAP 方案是治疗复发或难治性侵袭性 NHL 安全有效的解救方案之一。Objective To evaluate the efficacy and safety of ESHAP regimen,as a salvage regimen, in treating patients with relapsed or refractory aggressive NHL.Methods 38 patients with relapsed or refrac- tory aggressive NHL were selected to be treated by ESHAP regimen.Results The 38 patients received ES- HAP regimen with a range of 2～6 cycles. The total RR was 55.3 % with complete response(CR)rate of 26.3 %.The major toxicity was myelosuppression with infection,which was tolerable.Conclusion ESHAP regimen is one of safe and effective salvage regimens for the patients with relapsed or refractory aggressive NHL.

关 键 词：淋巴瘤 非霍奇金 抗肿瘤联合化疗方案 治疗 

分 类 号：R733.1[医药卫生—肿瘤]